What determines large scale galaxy clustering: halo mass or local density?

Using dark matter simulations we show how halo bias is determined by local density and not by halo mass. This is not totally surprising, as according to the peak-background split model, local density is the property that constraints bias at large scales. Massive haloes have a high clustering because they reside in high density regions. Small haloes can be found in a wide range of environments which determine their clustering amplitudes differently. This contradicts the assumption of standard Halo Occupation Distribution (HOD) models that the bias and occupation of haloes is determined solely by their mass. We show that the bias of central galaxies from semi-analytic models of galaxy formation as a function of luminosity and colour is not correctly predicted by the standard HOD model. Using local density instead of halo mass the HOD model correctly predicts galaxy bias. These results indicate the need to include information about local density and not only mass in order to correctly apply HOD analysis in these galaxy samples. This new model can be readily applied to observations and has the advantage that the galaxy density can be directly observed, in contrast with the dark matter halo mass.Comment: 11 pages, 9 figure

Acquired Cold Urticaria: Clinical Features, Particular Phenotypes, and Disease Course in a Tertiary Care Center Cohort

BACKGROUND: Data about special phenotypes, natural course, and prognostic variables of patients with acquired cold urticaria (ACU) are scarce. OBJECTIVES: We sought to describe the clinical features and disease course of patients with ACU, with special attention paid to particular phenotypes, and to examine possible parameters that could predict the evolution of the disease. METHODS: This study was a retrospective chart review of 74 patients with ACU who visited a tertiary referral center of urticaria between 2005 and 2015. RESULTS: Fourteen patients (18.9%) presented with life-threatening reactions after cold exposure, and 21 (28.4%) showed negative results after cold stimulation tests (classified as atypical ACU). Nineteen patients (25.7%) achieved complete symptoms resolution at the end of the surveillance period and had no subsequent recurrences. Higher rates of atypical ACU along with a lower likelihood of achieving complete symptom resolution was observed in patients who had an onset of symptoms during childhood (P < .05). In patients with atypical ACU, shorter disease duration and lower doses of antihistamines required for achieving disease control were detected (P < .05). Age at disease onset, symptom severity, and cold urticaria threshold values were found to be related to disease evolution (P < .05). LIMITATIONS: This study was limited by its retrospective nature. CONCLUSIONS: The knowledge of the clinical predictors of the disease evolution along with the clinical features of ACU phenotypes would allow for the establishment of an early and proper therapeutic strategy

Atmira Pharma Visualization

Atmira Pharma Visualization és un repte que presenta Cajamar UniversityHack 2022. Aquest repte consisteix en crear la millor aplicació i/o visualització de dades anonimitzades facilitades per Atida Mifarma, una empresa de comerç electrònic líder en Espanya i Portugal en la venta de productes de parafarmàcia i farmàcia. Així doncs, l'objectiu general del TFG és donar una visualització útil i completa per l'empresa Atida Mifarma que li permeti conèixer de forma visual dades rellevants pel seu dia a dia, a més d'ajudar la en la seva missió, visió i valors. A més, s'han realitzat dues recomanacions a l'empresa per tal que els seus clients siguin més proactius i ajudar al seu creixement.Atmira Pharma Visualization es un reto que presenta Cajamar UniversityHack 2022. Este reto consiste en crear la mejor aplicación y/o visualización de datos anonimizados facilitados por Atida Mifarma, una empresa de comercio electrónico líder en España y Portugal en la venta de productos de parafarmacia y farmacia. Así pues, el objetivo general del TFG es dar una visualización útil y completa por la empresa Atida Mifarma que le permita conocer de forma visual datos relevantes para su día a día, además de ayudarle en su misión, visión y valores. Además, se han realizado dos recomendaciones a la empresa para que sus clientes sean más proactivos y ayudar a su crecimiento.Atmira Pharma Visualization is a challenge presented by Cajamar UniversityHack 2022. This challenge consists in creating the best application and/or visualization of anonymized data provided by Atida Mifarma, a leading e-commerce company in Spain and Portugal in the sale of parapharmacy products and pharmacy. Therefore, the general objective of this Final Degree Project is to provide a useful and complete visualization for the company Atida Mifarma that allows them to visualize relevant data for their day to day, as well as help them in their mission, vision and values. In addition, two recommendations have been made to the company to make its customers more proactive and help them grow

BMP-2 induces osterix expression through upregulation of DLX5 and its phosphorylation by p38

Osterix, a zinc-finger transcription factor, is specifically expressed in osteoblasts and osteocytes of all developing bones. Because no bone formation occurs in Osterix null mice, Osterix is thought to be an essential regulator of osteoblast differentiation. We report that bone morphogenetic protein-2 (BMP-2) induces an increase in Osterix expression, which is mediated through a homeodomain sequence located in the proximal region of the Osterix promoter. Our results demonstrate that induction of Dlx5 by BMP-2 mediates Osterix transcriptional activation. First, BMP-2 induction of Dlx5 precedes the induction of Osterix. Second, Dlx5 binds to the BMP-responsive homeodomain sequences both in vitro and in vivo. Third, Dlx5 overexpression and knock-down assays demonstrate its role in activating Osterix expression in response to BMP-2. Furthermore, we show that Dlx5 is a novel substrate for p38 MAPK in vitro and in vivo and that Ser-34 and Ser-217 are the sites phosphorylated by p38. Phosphorylation at Ser-34/217 increases the transactivation potential of Dlx5. Thus, we propose that BMP activates expression of Osterix through the induction of Dlx5 and its further transcriptional activation by p38-mediated phosphorylation

Different polyphenol excretion between two populations following a 40th parallel diet

Podeu consultar el III Workshop anual INSA-UB complet a: http://hdl.handle.net/2445/118993Sessió 1. Pòster núm.

Edició i estudi preliminar de "La famosa comedia de la entrada del marqués de Los Vélez en Cataluña, rota de las tropas castellanas y asalto de Montjuïc"

En aquest treball, s'elabora l'estudi i l'edició de l'obra teatral titulada La famosa comedia de la entrada del Marqués de los Vélez, de 1641; únic exemple del teatre barroc basat en la Guerra dels Segadors. Primerament, es fa una reflexió sobre l'statu quo de la redacció de la peça i sobre l'autoria anònima. En segon lloc, es proposa una descripció de les seves unitats dramàtiques i personatges. S'exposa la seva transmissió textual i els criteris d'edició seguits. S'esposa una lectura interpretativa del nivell simbòlic, i, en darrer terme, s'exposa el text dramàtic establert amb les notes explicatives corresponents

Dual PI3K/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma

Phosphatidylinositol-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway activation contributes to mantle cell lymphoma (MCL) pathogenesis and drug resistance. Antitumor activity has been observed with mTOR inhibitors. However, they have shown limited clinical efficacy in relation to drug activation of feedback loops. Selective PI3K inhibition or dual PI3K/mTOR catalytic inhibition are different therapeutic approaches developed to achieve effective pathway blockage. Here, we have performed a comparative analysis of the mTOR inhibitor everolimus, the pan-PI3K inhibitor NVP-BKM120 and the dual PI3K/mTOR inhibitor NVP-BEZ235 in primary MCL cells. We found NVP-BEZ235 to be more powerful than everolimus or NVP-BKM120 in PI3K/Akt/mTOR signaling inhibition, indicating that targeting the PI3K/Akt/mTOR pathway at multiple levels is likely to be a more effective strategy for the treatment of MCL than single inhibition of these kinases. Among the three drugs, NVP-BEZ235 induced the highest change in gene expression profile. Functional validation demonstrated that NVP-BEZ235 inhibited angiogenesis, migration and tumor invasiveness in MCL cells. NVP-BEZ235 was the only drug able to block IL4 and IL6/STAT3 signaling which compromise the therapeutic effect of chemotherapy in MCL. Our findings support the use of the dual PI3K/mTOR inhibitor NVP-BEZ235 as a promising approach to interfere with the microenvironment-related processes in MCL